Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
Journal of Clinical Oncology · 01.06.2023 · 41 (16) · 2998-3008
DOI: 10.1200/jco.22.02241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2023. Verfasst von Marion T van Mackelenbergh und 29 weiteren Autor:innen. Beteiligte Einrichtung: Universitaetsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE The achievement of pathologic complete response (pCR) is strongly prognostic for event-free survival (EFS) and overall survival (OS) in patients with early breast cancer (EBC), and adapting postneoadjuvant therapy improves long-term outcomes for patients with HER2-positive disease not achieving pCR. We sought to investigate prognostic factors for EFS and OS among patients with and without pCR after neoadjuvant systemic treatment consisting of chemotherapy plus anti-HER2 therapy. MATERIALS AND METHODS We used individual data from 3,710 patients randomly assigned in 11 neoadjuvant trials for HER2-positive EBC with ≥100 patients enrolled, available data for pCR, EFS, and OS, and follow-up ≥3 years. We assessed baseline clinical tumor size (cT) and clinical nodal status (cN) as prognostic factors using stratified (by trial and treatment) Cox models separately for hormone receptor–positive versus hormone receptor–negative disease, and for patients who had pCR (pCR+; ypT0/is, ypN0) versus patients who did not achieve a pCR (pCR−). RESULTS The median follow-up overall was 61.2 months. In pCR+ patients, cT and cN were significant independent prognostic factors for EFS, whereas only cT was a significant predictor for OS. In pCR− patients, cT, cN, and hormone receptor status were significant independent predictors for both EFS and OS. Regardless of hormone receptor status, cT, and cN, the 5-year EFS/OS rates were higher in pCR+ patients than in pCR− patients. In most subsets with regards to hormone receptor and pCR status, cT and cN were independent prognostic factors for both EFS and OS, including pCR+ patients. CONCLUSION These results confirm that patients achieving pCR have far better survival outcomes than patients who do not. The traditional poor prognostic features, namely tumor size and nodal status, remain important even after a pCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Universitaetsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- German Breast Group, Neu-Isenburg, Germany.
- Helios Kliniken Berlin-Buch, Berlin, Germany.
- International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
- NSABP Foundation and University of Pittsburgh/Hillman Cancer Center, Pittsburgh, PA.
- San Raffaele Scientific Institute, Milan, Italy.
ORCID-Profile: Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Herve Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Richard Gelber, Everardo D Saad, Carsten Denkert, Javier Cortes, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael
Zitieren
APA
van Mackelenbergh, M. T., Loibl, S., Untch, M., Buyse, M., Geyer, C. E., Gianni, L., Schneeweiss, A., Conte, P., Piccart, M., Bonnefoi, H., Jackisch, C., Nekljudova, V., Tang, G., Valagussa, P., Neate, C., Gelber, R., Poncet, C., Squifflet, P., Saad, E. D., …, & CTNeoBC project (2023). Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer. Journal of Clinical Oncology, 41(16), 2998-3008. https://doi.org/10.1200/jco.22.02241
Vancouver
van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE, Gianni L, et al. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer. Journal of Clinical Oncology. 2023;41(16):2998-3008. doi:10.1200/jco.22.02241
BibTeX
@article{vanMackelenbergh2023,
author = {van Mackelenbergh, Marion T and Loibl, Sibylle and Untch, Michael and Buyse, Marc and Geyer, Charles E and Gianni, Luca and Schneeweiss, Andreas and Conte, Pierfranco and Piccart, Martine and Bonnefoi, Herve and Jackisch, Christian and Nekljudova, Valentina and Tang, Gong and Valagussa, Pinuccia and Neate, Colin and Gelber, Richard and Poncet, Coralie and Squifflet, Pierre and Saad, Everardo D and Heinzmann, Dominik and Denkert, Carsten and Rastogi, Priya and Cortes, Javier and Guarneri, Valentina and de Azambuja, Evandro and Cameron, David and Ismael, Gustavo and Wolmark, Norman and Cortazar, Patricia and CTNeoBC project, CTNeoBC project},
title = {Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {16},
pages = {2998--3008},
doi = {10.1200/jco.22.02241}
}
EUVIMED